Figure 5.

Inflammatory response of human microglia to α-synuclein preformed fibrils. Microglia were treated for 24 h with vehicle, Pam₃CSK₄ (100 ng/ml), lipopolysaccharide (LPS; 100 ng/ml) and/or α-synuclein (α-syn) preformed fibrils (PFFs) (1 μm). (A) Cytokine secretion from induced pluripotent stem cell-derived microglia (iMGL). Repeated measure one-way ANOVA were performed followed by Dunnett’s post hoc test. Mean ± SEM of n = 6; *P < 0.05, **P < 0.01. (B) Cytokine secretion from iMGL pretreated or not with UNC2025 (3 μm) or cytochalasin D (cyt D; 1 μm) for 1 h prior to vehicle/α-syn PFF treatment. Repeated measure one-way ANOVA were performed followed by Sidak’s post hoc test. Mean ± SEM of n = 4; **P < 0.01, ***P < 0.001. (C) Cytokine secretion from hMGL. Paired t-tests were performed. Mean ± SEM of n = 6; *P < 0.05. (D) Cytokine secretion from human primary microglia (hMGL). Repeated measure one-way ANOVA were performed followed by Sidak’s post hoc test. Mean ± SEM of n = 3; **P < 0.01. IL-1β = interleukin-1β; IL-6 = interleukin-6; IL-10 = interleukin-10; TNF = tumor necrosis factor.